search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Can Do Training in relapsing MS


- candidate number22444
- NTR NumberNTR5298
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR10-jul-2015
- Secondary IDsNL42205.028.12 METC499
- Public TitleCan Do Training in relapsing MS
- Scientific TitleControlled trial on the (cost)effectiveness of a Dutch Can Do Training (CDT) in persons with relapsing multiple sclerosis [Gecontroleerde Studie naar de (Kosten)Effectiviteit van een Nederlandse Can Do Training (CDT) bij Mensen met Relapsing Remitting Multipele Sclerose]
- ACRONYMG-CDT
- hypothesisIn people with relapsing remitting multiple sclerosis the self-efficacy control will be improved by a 3-day intensive social-cognitive program (Can Do treatment).
[Bij mensen met relapsing remitting multipele sclerose zal een intensieve 3-daagse sociaal-cognitive training (Can Do behandeling) de controle self-efficacy verbeteren.]
- Healt Condition(s) or Problem(s) studiedMultiple sclerosis (MS), Relapse, Disability
- Inclusion criteria1) diagnosis RRMS, 2) being diagnosed at least one year ago,3) EDSS score 4.0 or lower, 4) no symptoms suggestive of a relapse, 5) no relapse in the preceding 4 weeks, 6) willing and capable to participate in the investigations, 7) having access to the internet, and 8) having given informed consent.
- Exclusion criteria2) diagnosis progressive MS, 2) EDSS higher than 4.0, 3) ongoing relapse, 4) no informed consent
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-apr-2013
- planned closingdate1-jan-2017
- Target number of participants140
- Interventions3-day intensive social cognitive program
- Primary outcomeSelf-efficacy control
- Secondary outcomeSelf-efficacy function, autonomy and participation, quality of life, coping, anxiety, depression, cost effectiveness and cost utility.
- Timepoints01-07-2016 end of inclusion;01-01-2017 end of analyses.
- Trial web sitewww.ms4ri.nl
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES Astrid Hussaarts
- CONTACT for SCIENTIFIC QUERIESDr. Peter Joseph Jongen
- Sponsor/Initiator MS4 Research Institute
- Funding
(Source(s) of Monetary or Material Support)
Nationaal MS Fonds
- PublicationsNone
- Brief summaryNone
- Main changes (audit trail)
- RECORD10-jul-2015 - 20-aug-2015


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl